Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol
Tóm tắt
It is estimated that 29% of deaths in Australia are caused by malignant disease each year and can be expected to increase with population ageing. In advanced cancer, the prevalence of fatigue is high at 70–90%, and can be related to the disease and/or the treatment. The negative impact of fatigue on function (physical, mental, social and spiritual) and quality of life is substantial for many palliative patients as well as their families/carers. This paper describes the design of single patient trials (n-of-1 s or SPTs) of a psychostimulant, methylphenidate hydrochloride (MPH) (5 mg bd), compared to placebo as a treatment for fatigue, with a population estimate of the benefit by the aggregation of multiple SPTs. Forty patients who have advanced cancer will be enrolled through specialist palliative care services in Australia. Patients will complete up to 3 cycles of treatment. Each cycle is 6 days long and has 3 days treatment and 3 days placebo. The order of treatment and placebo is randomly allocated for each cycle. The primary outcome is a reduction in fatigue severity as measured by the Functional Assessment of Cancer Therapy-fatigue subscale (FACIT-F). Secondary outcomes include adverse events, quality of life, additional fatigue assessments, depression and Australian Karnovsky Performance Scale. This study will provide high-level evidence using a novel methodological approach about the effectiveness of psychostimulants for cancer-related fatigue. If effective, the findings will guide clinical practice in reducing this prevalent condition to improve function and quality of life. Australian New Zealand Clinical Trials Registry
ACTRN12609000794202
Tài liệu tham khảo
Australian Institute of Health and Welfare: Cancer in Australia: in brief 2010. 2010, Canberra: Australian Institute of Health and Welfare
Australian Bureau of Statistics: Australian Social Trends. March 2007, Cat. No. 4102.0. http://www.abs.gov.au/AUSSTATS/[email protected]/DetailsPage/4102.02007
Mock V, Atkinson A, Barsevick AM, Berger AM, Cimprich B, Eisenberger MA, Hinds P, Kaldor P, Otis-Green SA, Piper BF: Cancer-related fatigue. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007, 5: 1054-1078.
Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J: Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004, 32: 40-50.
Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR: Cancer-related fatigue: the scale of the problem. Oncologist. 2007, 12 (Suppl 1): 4-10.
Walsh D, Rybicki L: Symptom clustering in advanced cancer. Support Care Cancer. 2006, 14: 831-836. 10.1007/s00520-005-0899-z.
Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997, 34: 4-12.
Pharmaceutical Society of Australia: Australian medicines handbook 2005. 2005, Adelaide: Australian Medicines Handbook Pty Ltd
Nikles CJ, Glasziou PP, Del Mar CB, Duggan CM, Mitchell G: N of 1 trials. Practical tools for medication management. Aust Fam Physician. 2000, 29: 1108-1112.
Nikles J, Mitchell GK, Schluter P, Good P, Hardy J, Rowett D, Shelby-James T, Vohra S, Currow D: Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. J Clin Epidemiol. 2011, 64: 471-480. 10.1016/j.jclinepi.2010.05.009.
Schluter PJ, Ware RS: Single patient (n-of-1) trials with binary treatment preference. Stat Med. 2005, 24: 2625-2636. 10.1002/sim.2132.
Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J: Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997, 50: 401-410. 10.1016/S0895-4356(96)00429-5.
NCCN Cancer-Related Fatigue Panel: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Cancer-Related Fatigue V.1.2011.
Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997, 34: 13-19.
Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002, 55: 285-295. 10.1016/S0895-4356(01)00477-2.
Mallinson T, Cella D, Cashy J, Holzner B: Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage. 2006, 31: 229-241. 10.1016/j.jpainsymman.2005.07.012.
Wu HS, Wyrwich KW, McSweeney M: Assessing fatigue in persons with cancer: further validation of the Wu Cancer Fatigue Scale. J Pain Symptom Manage. 2006, 32: 255-265. 10.1016/j.jpainsymman.2006.06.001.
Lloyd-Williams M, Dennis M, Taylor F: A prospective study to compare three depression screening tools in patients who are terminally ill. Gen Hosp Psychiatry. 2004, 26: 384-389. 10.1016/j.genhosppsych.2004.04.002.
Lloyd-Williams M, Friedman T, Rudd N: Criterion validation of the Edinburgh postnatal depression scale as a screening tool for depression in patients with advanced metastatic cancer. J Pain Symptom Manage. 2000, 20: 259-265. 10.1016/S0885-3924(00)00182-2.
Cancer Therapy Evaluation Program: NCI Common Terminology Criteria for Adverse Events (CTCAE v4.0). Book NCI Common Terminology Criteria for Adverse Events (CTCAE v4.0). 2006
Hardy JR, Carmont SA, O'Shea A, Vora R, Schluter P, Nikles CJ, Mitchell GK: Pilot study to determine the optimal dose of methylphenidate for an n-of-1 trial for fatigue in patients with cancer. J Palliat Med. 2010, 13: 1193-1197. 10.1089/jpm.2010.0185.
Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL: Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006, 24: 2073-2078. 10.1200/JCO.2005.02.8506.
Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B: Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol. 1991, 18: 447-451.
Sarhill N, Walsh D, Nelson KA, Homsi J, LeGrand S, Davis MP: Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care. 2001, 18: 187-192. 10.1177/104990910101800310.
Schwartz AL, Thompson JA, Masood N: Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum. 2002, 29: E85-E90. 10.1188/02.ONF.E85-E90.
Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC: Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011, 41: 761-767. 10.1016/j.jpainsymman.2010.06.020.
Butler JM, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, Lesser G, McMullen K, McQuellon R, Naughton M: A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007, 69: 1496-1501. 10.1016/j.ijrobp.2007.05.076.
Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, Suh JJ, Griffin PC, Johnson DB, Ali A: Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010, 28: 3673-3679. 10.1200/JCO.2010.28.1444.
Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D: Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009, 38: 650-662. 10.1016/j.jpainsymman.2009.03.011.
Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC, Pisters K: A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med. 2003, 17: 659-663.
Bruera E, Schoeller T, MacEachern T: Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. J Pain Symptom Manage. 1992, 7: 365-368. 10.1016/0885-3924(92)90091-U.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-684X/12/17/prepub